French
Online Bookshop Home
www.oecd.org
Login  |   Your account  |   Bookshelf  |   View Shopping Basket Help
Search  for   in 
  Search Tips   •   Advanced Search
You are in > OECD Bookshop > Publication Page
Back

The Development Dimension
Coherence for Health
Innovation for New Medicines for Infectious Diseases
OECD Publishing
Version: Print (Paperback) + Free PDF
Price:   €24 | $32 | £20 | ¥3000 |   Discount Price: €12.00 | $16.00 | £10.00 | ¥1500 
Standard shipping included!
Add to basket Look inside Email-it    

Availability: Available  Publication date:  29 Apr 2009  Language: English  Pages: 148  ISBN: 9789264060142  OECD Code: 032009051P1 
 

Other Versions & Languages | Table of contents

In developing countries, 6 out of 10 people die from infectious diseases. Nearly 1 billion humans suffer from a neglected infectious disease, according to the World Health Organisation. Yet less than 1% of the new drugs placed on the market from 1975 to the turn of the century were developed for these diseases. This book looks at ways of improving the availability of medicines for infectious diseases through strengthened coherence in health, trade, science and technology, development co-operation and finance.

Other Versions:  E-book - PDF Format

Further reading:
Pharmaceutical Pricing Policies in a Global Market - (Reprinting)
Poverty and Health - (Available)



Table of contents:
  - Acronyms and Abbreviations
  - Neglected and Emerging Infectious Diseases - Why It Is An Issue Now
  - What Are the Problems? - Why Is It in the Economic Interest of OECD Countries to Address these Problems?
  - Present Policy Solutions Being Used to Address the Problems of Neglected Infectious Diseases
  - Moving Forward - Solutions and Next Steps
  - Annex A - Summaries of the High-Level Forum Preparatory Workshops
  - Annex B - The Basic Economics of Scaling Up Healthcare in Low-Income Settings
  - Annex C - OECD Country Policy Options for Increasing the Availability of Medicines for Neglected Diseases
  - Annex D - Improving the Access to Essential Medicines in Low-Income Countries

Back Back to top